Autism Speaks Be Informed Get Involved Walk Events Community Science
About Us
Goals
Leadership
In the News
Press Releases
What is Autism
Video Glossary
What to Do About It
How to Cope
How to Grow With It
Navigating the Spectrum
Donate
Online Store
Tributes
Our Events
Calendar
Government Affairs
Family Services
Resources
Outreach
Chapters
Student Clubs
Message Boards
Overview
Science News
Research
Portfolios
Grant Program
Initiatives
Resources/Programs
Scientific Meetings
 
CAN Archive
News Archive
Current News
NAAR Archive
Goals
About Us
Leadership
In the News
Press Releases
FDA Approves Risperdal for Treatment of Irritability Associated with Autistic Disorder
The U.S. Food and Drug Administration (FDA) has approved the use of Risperdal for the treatment of irritability associated with autistic disorder. This is the first time the FDA has approved a drug for the treatment of symptoms of autism in children and adolescents. The drug is marketed by Janssen, L.P, a subsidiary of Johnson & Johnson.

Click here for the company press release. Click here to read a news story from Reuters.
Click to Sign-up for e-Speaks Newsletter